Case Details
- Citation: [2011] SGHC 71
- Case Title: Martek Biosciences Corporation v Cargill International Trading Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 29 March 2011
- Judge: Tay Yong Kwang J
- Coram: Tay Yong Kwang J
- Case Number: Originating Summons No. 156 of 2010
- Tribunal/Body Below: Deputy Registrar of Patents and Principal Assistant Registrar of Patents (the “Tribunal”)
- Proceedings Below: Revocation Proceedings and Amendment Proceedings consolidated
- Hearing Dates Below: 16 to 18 February 2009
- Date of Tribunal Decision: 31 December 2009
- Applicant/Proprietor: Martek Biosciences Corporation
- Respondent: Cargill International Trading Pte Ltd
- Legal Area: Patents and Inventions
- Patent at Issue: Singapore Patent P-No. 49307, entitled “Microbial Oil Mixtures and Use Thereof”
- Application Date: 13 April 1996
- Grant Date: 10 January 2002
- Statutory Provisions Referenced (as stated in extract): Patents Act (Cap 221, 2005 Rev Ed) including ss 80(1)(a), 80(1)(c), 80(1)(d)(i), 83, 84(3)(a), 80(2); Patents Rules (Cap 221, R1, 1996 Rev Ed) including r 80(3), r 85(1), r 81(1)(a); Evidence Act (as referenced in metadata)
- Counsel for Applicant: Dr Stanley Lai, SC and Mr Vignesh Vaerhn (Allen & Gledhill LLP)
- Counsel for Respondent: Mr Daniel Koh (instructed) (Eldan Law LLP) and Ms Wendy Low Wei Ling (Rajah & Tann LLP)
- Witnesses (Statutory Declarations) for Respondent: Dr Puah Chum Mok; Dr Nga Been Hen
- Witnesses (Statutory Declarations) for Applicant: Dr Eric Lien; Dr David Kyle
- Prior Art Focused on (before High Court): D1, D2, D3, D27, D34
- Prior Art Identified: D1 EP0404058A2 (published 27 Dec 1990); D2 Yongmanitchai & Ward; D3 EP0231904A2 (published 12 Aug 1987); D27 Carlson et al (INFORM 1990 abstracts); D34 Sanders & Roshanai (Clinical Science 1983)
- Length of Judgment: 19 pages, 10,185 words (as provided)
- Cases Cited: [2011] SGHC 71 (as provided in metadata)
Summary
Martek Biosciences Corporation v Cargill International Trading Pte Ltd [2011] SGHC 71 concerned a patent revocation challenge and disputes over the allowability of multiple sets of amendments to a Singapore patent relating to “Microbial Oil Mixtures and Use Thereof”. The High Court (Tay Yong Kwang J) heard appeals and cross-appeals arising from a Tribunal decision that had allowed revocation on broad grounds and had rejected many amended claims on patentability and/or sufficiency, while also addressing objections to the proposed amendments.
On appeal, the High Court allowed the Applicant’s appeal against the Tribunal’s decision in the revocation proceedings, dismissing both parties’ appeals and cross-appeals against the Tribunal’s decisions on amendment objections except in relation to Claim 42 and, consequently, Claim 45 in the Proposed 2006 Amendments. The practical effect was that the patent was not revoked on the grounds accepted by the Tribunal, but certain amended claims were still not permitted (at least as to Claim 42 and Claim 45).
What Were the Facts of This Case?
The Applicant, Martek Biosciences Corporation, is a Delaware-incorporated company. The Respondent, Cargill International Trading Pte Ltd, is incorporated in Singapore. Martek was the proprietor of Singapore Patent P-No. 49307, entitled “Microbial Oil Mixtures and Use Thereof”. The patent application was filed on 13 April 1996 and granted on 10 January 2002. The invention, as described in the abstract, concerned compositions including blends of microbial oils, methods of using such compositions—particularly as supplements for infant formula—and methods of increasing the amount of long chain polyunsaturated fatty acids in infant formula.
The patent’s technical subject matter sits within the chemistry and nutrition of polyunsaturated fatty acids (PUFAs) and long chain polyunsaturated fatty acids (lcPUFAs). The judgment explains that a PUFA is an unsaturated fatty acid with at least two carbon double bonds in its fatty acid tail, while an lcPUFA is a PUFA with at least 20 carbon atoms in its fatty acid tail. The patent’s relevance to infant formula stems from the nutritional importance of lcPUFAs such as arachidonic acid (ARA, an omega-6 lcPUFA) and docosahexaenoic acid (DHA, an omega-3 lcPUFA).
Before grant, Martek filed two sets of amendments: the 1997 Amendments (dated 2 July 1997) and the 1999 Amendments (dated 13 October 1999). After grant, the Respondent initiated revocation proceedings. On 20 January 2006, Cargill applied to revoke the patent on three grounds under the Patents Act: (1) that the invention was not a patentable invention under section 80(1)(a); (2) insufficiency, namely that the specification did not disclose the invention clearly and completely for it to be performed by a person skilled in the art, under section 80(1)(c); and (3) that the 1999 Amendments disclosed matter beyond what was disclosed in the application as filed, under section 80(1)(d)(i).
In response, Martek filed a counter statement and proposed further amendments. It filed Proposed 2006 Amendments pursuant to section 83 of the Patents Act and Rule 80(3) of the Patents Rules. These were advertised in The Patents Journal on 30 October 2006, and during the opposition period Cargill filed a notice of opposition alleging that the Proposed 2006 Amendments extended subject matter beyond the original application, contrary to section 84(3)(a). Martek then obtained leave to file Proposed 2008 Amendments (19 March 2008), which were advertised on 28 May 2008. Cargill objected by letter dated 27 March 2008, alleging that the amendments extended the protection conferred by the patent. At a case management conference, the Hearing Officers indicated an intention to re-examine the patent under section 80(2), and Cargill requested re-examination under Rule 81(1)(a). A re-examination report was made available on 6 January 2009. The Tribunal consolidated the revocation and amendment proceedings and heard them together in February 2009.
What Were the Key Legal Issues?
The High Court had to consider, first, whether the Tribunal was correct in allowing revocation of the patent. The revocation grounds invoked by Cargill required the court to assess patentability under section 80(1)(a), sufficiency under section 80(1)(c), and whether the 1999 Amendments introduced added subject matter beyond the original disclosure under section 80(1)(d)(i). These issues are central to Singapore patent practice because they determine whether a granted patent (and its amended form) remains legally enforceable.
Second, the High Court had to address the amendment-related disputes. Under the Patents Act framework, amendments to claims after grant must satisfy statutory requirements, including that they do not add matter beyond the application as filed and that they are allowable within the limits set by the Act. Cargill’s objections to the Proposed 2006 and Proposed 2008 Amendments raised questions about whether certain claims extended protection or introduced impermissible subject matter. The High Court’s disposition indicates that most of the Tribunal’s amendment rulings were upheld, but Claim 42 (and therefore Claim 45) in the Proposed 2006 Amendments required different treatment.
Third, the case also turned on evidential and procedural matters relating to expert evidence. The judgment highlights that one of Cargill’s expert witnesses, Dr Puah, was withdrawn from taking the stand, leaving his statutory declaration untested by cross-examination. The court also scrutinised the objectivity and expertise of another expert, Dr Nga, and the Tribunal’s approach to bias and hindsight. These issues matter because patent disputes frequently depend on expert interpretation of technical disclosures and prior art.
How Did the Court Analyse the Issues?
The High Court adopted an analytical approach that the judge considered preferable to the Tribunal’s. The Tribunal had examined the allowability of each set of amendments before examining validity as amended by each set. The High Court considered that it would be “a better approach” to first examine whether the patent is valid in the first place and, if it is, then to examine whether the respective sets of amendments are allowable. This methodological choice reflects a practical sequencing concern: if the core patent is not valid, amendment allowability may become academic; conversely, if the patent is valid, amendment issues can be assessed against a stable baseline.
In the appeal, the Respondent did not appeal against the Tribunal’s decision to allow the 1999 Amendments (save for Claim 30). Accordingly, the High Court focused on the validity of the patent as amended by the 1999 Amendments (excluding Claim 30). If that validity assessment succeeded for the Applicant, the court would then examine the allowability of the Proposed 2006 and Proposed 2008 Amendments. This structure shows how the court treated the 1999 Amendments as a key “platform” for assessing patentability and sufficiency, and it narrowed the scope of the revocation appeal.
On the evidential front, the High Court identified significant concerns about the Respondent’s expert evidence. Dr Puah’s statutory declaration was not cross-examined because the Respondent withdrew him from the stand. The judgment treats this as a “significant issue” and addresses it later in the judgment. In patent litigation, where expert evidence is often used to interpret prior art and the specification, the inability to test evidence through cross-examination can affect the weight that should be given to that evidence. The High Court’s attention to this point suggests that the Tribunal may have relied too heavily on untested expert assertions.
The court also addressed the Tribunal’s treatment of Dr Nga’s evidence. Dr Nga admitted that he was not an expert in the use of microbial oils in the human diet and not a specialist in paediatric nutrition. He further admitted that his conclusions on prior art documents were made with the benefit of hindsight after reading the patent. The Tribunal therefore held it would be “cautious” about relying on his evidence. The High Court’s analysis indicates that the court considered the credibility and relevance of expert testimony in determining whether the prior art truly disclosed the claimed invention, and whether the claimed invention would have been obvious or not patentable at the relevant time.
Although the extract provided does not include the full reasoning on the substantive patentability, sufficiency, and added subject matter grounds, the High Court’s ultimate disposition—allowing the Applicant’s appeal against revocation—implies that the court found errors in the Tribunal’s conclusions or that the Respondent failed to meet the statutory threshold for revocation. In patent revocation proceedings, the burden and standard of proof are critical: the challenger must establish the statutory grounds for revocation. The High Court’s willingness to overturn the revocation outcome suggests that the Tribunal’s findings on patentability and/or sufficiency were not supported to the required standard, particularly in light of the evidential weaknesses identified.
For the amendment proceedings, the High Court dismissed both parties’ appeals and cross-appeals except regarding Claim 42 and Claim 45 in the Proposed 2006 Amendments. This indicates that most of the Tribunal’s determinations on allowability were upheld. The carve-out for Claim 42 and Claim 45 suggests a targeted correction—likely because those claims either failed the statutory test for amendment allowability or, conversely, should have been allowed based on the proper construction of the original disclosure and the amended claim scope. The court’s “except with regard” language underscores that the amendment dispute was not wholesale; it was claim-specific.
What Was the Outcome?
The High Court allowed Martek’s appeal against the Tribunal’s decision in the revocation proceedings. In practical terms, this meant that the patent was not revoked on the grounds accepted by the Tribunal. The High Court’s decision therefore preserved the patent’s enforceability, subject to the remaining amendment-related limitations.
As to the amendment proceedings, the High Court dismissed both parties’ appeals and cross-appeals against the Tribunal’s decision relating to objections to Martek’s various sets of amendments, except that it addressed Claim 42 and, consequently, Claim 45 in the Proposed 2006 Amendments. The effect is that the patent’s amended claim set was adjusted: most amended claims remained as determined by the Tribunal, but Claim 42 (and Claim 45) required different treatment consistent with the High Court’s ruling.
Why Does This Case Matter?
This case matters for practitioners because it illustrates how Singapore courts approach the interplay between revocation and amendments. The High Court’s sequencing preference—assessing validity first and then amendment allowability—provides a useful framework for litigators planning arguments and evidence. It also highlights that amendment disputes should not distract from the core statutory question of whether the patent, as properly amended, is valid.
Martek v Cargill also underscores the importance of expert evidence management. The court’s focus on the withdrawal of an expert from the stand (leaving a statutory declaration untested by cross-examination) and its scrutiny of an expert’s domain expertise and hindsight bias are practical reminders for patent litigants. Expert evidence in technical patent cases must be both relevant and properly tested; otherwise, its evidential weight may be reduced, affecting the outcome on patentability and sufficiency.
Finally, the case is significant for claim-drafting and amendment strategy. The High Court’s partial intervention on Claim 42 and Claim 45 demonstrates that amendment allowability can turn on fine distinctions in claim scope and how the amended claim relates to the original disclosure. For patent owners, the decision reinforces the need to ensure that amendments remain within the boundaries of what was disclosed in the application as filed and that any narrowing or re-framing of claims is done in a legally defensible manner.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed) (“Patents Act” / “Act”), including sections 80(1)(a), 80(1)(c), 80(1)(d)(i), 80(2), 83, 84(3)(a), and section 116(6) (as referenced in the metadata/extract)
- Patents Rules (Cap 221, R1, 1996 Rev Ed), including Rules 80(3), 85(1), and 81(1)(a) (as referenced in the extract)
- Evidence Act (as referenced in metadata)
Cases Cited
- [2011] SGHC 71 (as provided in metadata)
Source Documents
This article analyses [2011] SGHC 71 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.